Atea and Roche get a Covid-19 antiviral warning
The failure of the phase 2 Moonsong outpatient trial prompts a phase 3 rethink and a one-year delay.
Medtronic faces a denervation delay
And when the long-awaited trial does finally report it will have to be a smash hit.
ANA 2021 – Ionis rocked by tofersen flop
After the Valor defeat, the group and its partner Biogen will hope that going earlier could improve the amyotrophic lateral sclerosis project’s chances.
Treme climbs a new mountain
Astrazeneca’s Himalaya study is a surprising hit in first-line liver cancer, but competition is already present.
A remyelinating agent remains a distant hope
But the pipeline contains various approaches that are worth watching, with data from Abbvie possibly the next big event.
Crispr’s reminder about allogeneic Car-T redosing
Crispr follows Allogene with backing for off-the-shelf Car-T therapy – and adds big concerns over lack of durability.
Atara claims a remyelination signal
The company’s off-the-shelf T-cell immunotherapy seems to be improving multile sclerosis disability, but an ongoing phase 2 trial will provide a better test.
